Compare Crispr Therapeutics AG (CRSP) vs Mercadolibre Inc (MELI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Mercadolibre Inc — how do they compare? Crispr Therapeutics AG trades at $54.21 (market cap $5.23B), while Mercadolibre Inc trades at $1,847.65 (market cap $98.35B). The key difference: Mercadolibre Inc is far larger — about 18.8× Crispr Therapeutics AG's market cap, and Mercadolibre Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | MELI | |
|---|---|---|
Market Cap | $5.23B | $98.35B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $2.51K |
52-Week Low | $44.34 | $1.55K |
Enterprise Value | $3.65B | $106.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
MercadoLibre (MELI) trades at $1,876, up 2.83% today, with strong technical momentum and bullish moving average signals. The company reported Q2 2026 EPS of $9.19, beating estimates, while revenue grew 50% year-over-year to exceed $10 billion for the first time. Analyst consensus remains strongly bullish with 23 buy ratings and a $2,150 price target, though margin compression from strategic investments has tempered near-term profit growth.
MELI's growth-first strategy is driving market share gains but pressuring margins, creating a tension between rapid expansion and profitability. The stock offers significant upside to analyst targets but faces execution risks from increased competition and macroeconomic volatility in Latin America. Long-term investors may find value in the ecosystem growth, while short-term volatility could persist amid margin concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →
